Press release
Pertussis Vaccine Market Poised for Growth Through 2032 Driven by Increasing Prevalence and Advancing Vaccine Pipeline | DelveInsight
Pertussis Market Insight, Epidemiology And Market Forecast - 2032
DelveInsight's "Pertussis Market Insight, Epidemiology And Market Forecast - 2032 [https://www.delveinsight.com/report-store/pertussis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr]" report provides comprehensive insights into Pertussis, including historical and forecasted epidemiology data, current treatment practices, and the pertussis market trends across the seven major markets including US, EU4 (Germany, France, Italy, and Spain), the UK, and Japan. The report forecasts significant market expansion during the period from 2023 to 2032, primarily attributed to rising disease awareness and the introduction of novel vaccines with improved efficacy profiles.
Furthermore, the US emerged as the largest pertussis market, followed by Germany in 2022. This trend is expected to continue during the forecast period through 2032.
Download the Pertussis Market Forecast Report to understand which factors are driving the Pertussis market @ Pertussis Market Trends [https://www.delveinsight.com/sample-request/pertussis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr].
Pertussis, commonly known as whooping cough, is an acute respiratory infection caused by the bacterium Bordetella pertussis. The disease progresses through three distinct stages, catarrhal, paroxysmal, and convalescent, with accurate and timely diagnosis often challenging due to symptom overlap with other respiratory conditions. Various diagnostic approaches include culture testing, polymerase chain reaction (PCR), and serological assays, with paired sera testing demonstrating the highest diagnostic accuracy.
The report's epidemiological analysis reveals that pertussis vaccination coverage in the US reached approximately 19 million individuals in 2022, with the highest coverage observed in the adult population aged 18 years and older, accounting for approximately 5 million vaccinations. Across the 7MM, the total population vaccinated against pertussis was estimated at approximately 34 million in 2022, with projections indicating steady growth in the pertussis vaccination rate over the forecast period from 2023 to 2032, based on trends in vaccination coverage and public health initiatives.. Notably, while childhood vaccination rates remain high across major markets, booster vaccination compliance among adults has been comparatively lower, presenting opportunities for market expansion through increased awareness and updated immunization recommendations.
Discover evolving trends in the Pertussis patient pool forecasts @ Pertussis Epidemiological Analysis [https://www.delveinsight.com/sample-request/pertussis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr].
The current pertussis treatment landscape is primarily focused on prevention through vaccination, with treatment options being largely supportive and antibiotic-based. Two key vaccines in the United States help prevent whooping cough: DTaP and Tdap, which are typically administered in combination with vaccines for diphtheria and tetanus, and sometimes poliomyelitis, H. influenzae, and hepatitis B. The market is dominated by established vaccine products, including ADACEL from Sanofi Pasteur (EPA: SAN) and BOOSTRIX from GlaxoSmithKline (LON: GSK). ADACEL, a trivalent booster vaccine indicated for active immunization against pertussis, tetanus, and diphtheria, is recommended for individuals from 4 years of age following primary immunization and is available in several countries globally. Meanwhile, BOOSTRIX is indicated for active booster immunization in individuals aged 10 and older. It is routinely recommended in the US for immunization of pregnant women.
Despite high vaccination coverage in Europe, the most recent ECDC data confirm that pertussis incidence is rising in several European countries and that adults, including middle-aged populations. This underscores critical immunity gaps in middle-aged populations, driving calls for adult booster campaigns and next-generation vaccines with prolonged efficacy.
The pertussis pipeline features a wave of innovation aimed at addressing these challenges of waning immunity and rising adult cases. Notably, the Serum Institute of India is advancing a next-generation acellular pertussis vaccine composed of purified antigenic components such as pertussis toxoid, filamentous haemagglutinin, and pertactin, currently undergoing toxicology studies in the UK, with plans for global rollout in the next two years. In December 2024, ILiAD Biotechnologies partnered with hVIVO and is preparing to launch a pivotal phase III trial in the second half of 2025 for BPZE1, a novel intranasal live attenuated pertussis vaccine designed to induce robust mucosal immunity and potentially provide longer-lasting protection.
Discover evolving trends in the Pertussis treatment landscape @ Pertussis Recent Developments [https://www.delveinsight.com/sample-request/pertussis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr].
The pertussis vaccine market is highly competitive and dominated by major global pharmaceutical companies such as GlaxoSmithKline (NYSE: GSK), Sanofi Pasteur (EPA: SAN), Pfizer (NYSE: PFE), and Merck (NYSE: MRK), alongside strong regional players like Serum Institute of India, Mitsubishi Tanabe Pharma (TYO: 4508), Biological E. Limited, and others.
Looking ahead, the pertussis therapeutic market is experiencing steady growth driven by rising birth rates, ongoing immunization programs, and the growing adoption of combination vaccines like DTaP and hexavalent formulations. The Competition is further intensified by continuous research and development, new product launches, and strategic collaborations among established companies and emerging biotech firms. While barriers to entry remain high due to regulatory and manufacturing complexities, established players are focused on expanding global access, improving vaccine efficacy, and strategic partnerships to drive the market growth.
Table of Contents
1. Key Insights
2. Report Introduction
3. Pertussis Market Overview at a Glance
4. Executive Summary of Pertussis
5. Key Events
6. SWOT Analysis
7. Disease Background and Overview
8. Prophylactic Treatment
9. Antibiotic Treatment
10. CCDC Guidelines on Vaccination of Pertussis for Infants, Children, Adolescents, Pregnant Women, and Adults (2020)
11. American College of Obstetricians and Gynecologists (ACOG) Guidelines for Pertussis Vaccination in the United States (2020)
12. Standing Committee on Vaccination (STIKO) Guidelines for Pertussis Vaccination in Germany (2018)
13. Public Health England Guidelines for Management of Pertussis in the UK (2018)
14. Epidemiology and Patient Population
15. Organizations contributing toward Pertussis
16. Pertussis Patient Journey
17. Pertussis Marketed Vaccines
18. Pertussis Emerging Vaccines
19. Potential of Current and Emerging Vaccines
20. Pertussis: Seven Major Markets Analysis
21. KOL Views
22. Unmet Needs
23. Market Access and Reimbursement
24. Appendix
25. DelveInsight Capabilities
26. Disclaimer
27. About DelveInsight
Related Reports
Pertussis Pipeline Insight [https://www.delveinsight.com/sample-request/pertussis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr]
Pertussis Pipeline Insight provides comprehensive insights about the Pertussis pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the Pertussis companies, including Tianjin CanSino Biotechnology, ILiAD Biotechnologies, LG Chem, BioNet-Asia, Intravacc, and VAXFORM LLC, among others.
About DelveInsight
DelveInsight is a leading market research and consulting firm specializing in disease-specific insights and therapeutic market analysis. Their reports integrate real-world data, clinical trial findings, and expert interviews to deliver comprehensive industry intelligence.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Arpit Anand
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=pertussis-vaccine-market-poised-for-growth-through-2032-driven-by-increasing-prevalence-and-advancing-vaccine-pipeline-delveinsight]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Pertussis Vaccine Market Poised for Growth Through 2032 Driven by Increasing Prevalence and Advancing Vaccine Pipeline | DelveInsight here
News-ID: 4015641 • Views: …
More Releases from ABNewswire
Understanding Magnetic Switches: Types, Working Principles, and Applications
A magnetic switch is a versatile electrical device that operates by responding to magnetic fields. From Hall Effect to reed switches, explore their functions, types, and diverse applications.
What is a Magnetic Switch?
A magnetic switch is an electrical device that operates by responding to the presence of a magnetic field. It functions by closing or opening its contacts based on the strength of the magnetic field. Specifically, the switch remains closed…
Innovating embedded downlight technology: Leading the global trend of intelligen …
The strong rise of China's manufacturing industry has profoundly reshaped the technological landscape and development trajectory of embedded downlights. With its unparalleled industrial chain advantages, continuous technological innovation, and significant cost-effectiveness, Chinese enterprises have risen from participants in the global lighting industry to undisputed leaders. This transformation goes far beyond the huge production scale; it lies in the thorough innovation of the core technical content and application boundaries of embedded…
North China Electric Power University Foreign Aid Training Program Visits Yiyuan …
On July 23, 2025, the Electrical Industry Training Program of North China Electric Power University's Foreign Aid Project visited Yiyuan Technology for an exchange visit. The purpose was to gain in-depth insights into the company's innovations in renewable energy technology promotion and application [https://www.yiyen.com/about/], and to build bridges connecting university-enterprise cooperation with foreign aid initiatives.
Image: https://ecdn6.globalso.com/upload/p/1108/image_other/2025-07/scene-1.jpg
Image: https://ecdn6.globalso.com/upload/p/1108/image_other/2025-07/scene-3.jpg
Upon arrival, the delegation received a warm welcome from company leadership and the reception…
Pure Sine Wave Low Frequency Inverter Charger
Pure sine wave low frequency inverter [https://www.yiypower.com/ap-mini-600w-1500w-120v-low-frequency-pure-sine-wave-inverter-charger-product/] is widely used and suitable for a variety of scenarios. In terms of home backup power, it can provide reliable power during power outages, ensuring that essential appliances such as refrigerators, air conditioners and medical equipment continue to operate . For solar power generation systems, Inverter charger [https://www.yiypower.com/ap-mini-600w-1500w-120v-low-frequency-pure-sine-wave-inverter-charger-product/] can converter DC Power from Battery, which charged by solar panels, into clean alternating current…
More Releases for Pertussis
Diphtheria, Pertussis, and Tetanus Vaccine Market
According to a new report published by Allied Market Research, titled, "Diphtheria, Pertussis, and Tetanus Vaccine Market by Product Type [DTaP (Daptacel, Infanrix, Kinrix, Pediarix, Pentacel, and Quaracel), Td (Decavac and Tenivac), and Tdap (Boostrix and Adacel)], Vaccine Type (Whole-Cell Vaccine and Acellular Vaccine), Age Group (Adult and Pediatric), and End User (Hospitals, Clinics, and Vaccination Centers) - Global Opportunity and Forecast, 2019-2026 ".
The Global market size of Diphtheria, Pertussis,…
Growth in Adoption of Pertussis Vaccination and Government Insurance are Project …
Pertussis vaccine is used for whooping cough. This vaccine is available only in combination with other vaccines. Pertussis vaccination is recommended for all children, babies, teens, and pregnant women. Diphtheria, tetanus, and pertussis (DTaP) vaccines are given to children younger than seven years old, while tetanus, diphtheria, and pertussis (Tdap) vaccines are given to older children and adults. Childhood vaccination is one of the safest and cost-effective ways for pertussis-free…
Global Pertussis Vaccine Consumption 2016 Market Research Report
The Global Pertussis Vaccine Consumption 2016 Market Research Report is a professional and in-depth study on the current state of the Pertussis Vaccine market.
First, the report provides a basic overview of the Pertussis Vaccine industry including definitions, classifications, applications and industry chain structure. And development policies and plans are discussed as well as manufacturing processes and cost structures.
Secondly, the report states the global Pertussis Vaccine market size (volume and value),…
Pertussis Vaccine Market: Estimated to Flourish by 2016 - 2024
The Pertussis Vaccine Market report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size.
Geographically, the pertussis vaccine market is classified into North America, Latin America, Europe, Asia Pacific, and Middle East & Africa. North America dominates the pertussis vaccine market due to growth in number of geriatric population and increase in pertussis death rate in the U.S,…
Pertussis Vaccine Industry 2024 Market Research Report
Pertussis vaccine is used for whooping cough. This vaccine is available only in combination with other vaccines. Pertussis vaccination is recommended for all children, babies, teens, and pregnant women. Diphtheria, tetanus, and pertussis (DTaP) vaccines are given to children younger than seven years old, while tetanus, diphtheria, and pertussis (Tdap) vaccines are given to older children and adults. Childhood vaccination is one of the safest and cost-effective ways for pertussis-free…
Pertussis Vaccine Industry 2024 Market Research Report
Pertussis vaccine is used for whooping cough. This vaccine is available only in combination with other vaccines. Pertussis vaccination is recommended for all children, babies, teens, and pregnant women. Diphtheria, tetanus, and pertussis (DTaP) vaccines are given to children younger than seven years old, while tetanus, diphtheria, and pertussis (Tdap) vaccines are given to older children and adults. Childhood vaccination is one of the safest and cost-effective ways for pertussis-free…
